Zeffix 100mg 28 tablets — Made in Poland — Free Delivery

Zeffix tablets are indicated for chronic viral hepatitis B in adults against the background of hepatitis B virus replication.

Active substance: lamivudine;

1 tablet contains 100 mg of lamivudine;

Excipients: microcrystalline cellulose, sodium starch (type A), magnesium stearate, shell YS-1R-17307-A (hypromellose, titanium dioxide (E 171), synthetic yellow iron oxide (E172), synthetic red iron oxide (E172), macrogol 400, polysorbate 80).

Zeffix is ​​contraindicated in case of hypersensitivity to lamivudine or other components of the preparation.

The recommended dose of Zeffix is ​​100 mg once a day.

Patients who cannot swallow tablets are advised to use Zeffix in the form of an oral solution.

The preparation should be taken with or without food. Swallow the tablet whole with water.

During treatment, it is imperative to monitor patient compliance with the therapy regimen.

Discontinuation of Zeffix treatment is possible for patients with normal immunity indicators after achieving seroconversion of HBeAg and HBsAg. The question of discontinuation of treatment should also be considered in case of ineffectiveness of therapy is manifested by a relapse of hepatitis.

After discontinuation of Zeffix therapy, dynamic monitoring of patients is recommended in order to timely detect a possible relapse of the disease.

It is not recommended to discontinue treatment in patients with decompensated stage of liver disease. Currently, there are limited data on the maintenance of seroconversion for a long time after discontinuation of Zeffix therapy.

Zeffix can be used during pregnancy if clinically needed.

Not recommended for use.

Carefully.

Information on the consequences of acute overdose in humans is limited. Lethal cases were not recorded, the condition of all patients returned to normal. There were no specific signs and symptoms of overdose.

In case of overdose, it is recommended to monitor the patient's condition and carry out standard supportive therapy. Given that lamivudine is dialyzed, continuous hemodialysis can be used, but no specific studies have been conducted.

The most common: malaise and fatigue, respiratory tract infections, discomfort in the throat and tonsils, headache, abdominal discomfort and pain, nausea, vomiting and diarrhea.

Due to its similarities, Zeffix should not be administered concurrently with other cytidine analogs such as emtricitabine. In addition, Zeffix should not be used in conjunction with any other medicinal product containing lamivudine.

Store at a temperature not exceeding 30 ° C.

Keep out of the reach of children.

Shelf life is 3 years.